Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
Asian Journal of Andrology|July 14, 2021
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trialByung Ha Chung, Jian Huang, Zhang-Qun Ye, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Oncotarget|February 13, 2014
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancerFrancesco Crea, Akira Watahiki, Luca Quagliata, et al.
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
The Lancet. Oncology|May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trialKarim Fizazi, Michael J Morris, Neal D Shore, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
Asian Journal of Andrology|July 14, 2021
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trialByung Ha Chung, Jian Huang, Zhang-Qun Ye, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Oncotarget|February 13, 2014
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancerFrancesco Crea, Akira Watahiki, Luca Quagliata, et al.
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
The Lancet. Oncology|May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trialKarim Fizazi, Michael J Morris, Neal D Shore, et al.
Pageof 24